- Merck KGaA‘s adjusted EBITDA for Q2 2024 stands at €1.51 billion, surpassing the estimated €1.42 billion despite a 2.8% decrease year-over-year.
- Healthcare adjusted EBITDA reached €720 million, exceeding the €696.7 million estimate.
- Life Science adjusted EBITDA came in at €655 million, slightly above the €650.6 million estimate.
- Electronics adjusted EBITDA was €255 million, surpassing the €225.4 million estimate.
- Overall adjusted EBITDA margin stood at 28.2%, down from 29.3% year-over-year but above the 27.5% estimate.
- Healthcare adjusted EBITDA margin was 33.7%, marginally below the 33.8% estimate.
- Life Science adjusted EBITDA margin met the estimate at 29%.
- Electronics adjusted EBITDA margin was 26.7%, above the 25.1% estimate.
- Net sales for Q2 2024 were €5.35 billion, a 0.9% increase year-over-year, and above the estimated €5.23 billion.
- Healthcare net sales were €2.14 billion, up 4.3% year-over-year, surpassing the €2.09 billion estimate.
- Bavencio sales were €186 million, up 4.5% year-over-year but below the estimated €198.8 million.
- Rebif sales totaled €168 million, an 18% decrease year-over-year but above the estimated €162.6 million.
- Mavenclad sales reached €266 million, a 1.5% increase year-over-year but below the estimated €279.2 million.
- Life Science net sales were €2.26 billion, a 4.1% decrease year-over-year, in line with the €2.25 billion estimate.
- Electronics net sales were €957 million, a 6.5% increase year-over-year, beating the €900.3 million estimate.
- EBIT stood at €792 million, an 18% decrease year-over-year and below the estimated €919.2 million.
- Adjusted EPS was €2.20, matching the previous year’s figure and above the estimated €2.01.
- Year Forecast:
- Adjusted EBITDA is projected to be between €5.8 billion and €6.4 billion, with an estimate of €6.07 billion.
- Net sales are expected to be between €20.7 billion and €22.1 billion, with an estimate of €21.3 billion.
- Adjusted EPS is predicted to be between €8.20 and €9.30, with an estimate of €8.64.
A look at Merck KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Merck KGaA‘s long-term outlook appears to be positive. The company scores well in Growth and Momentum, indicating promising prospects for expansion and strong market performance. Additionally, with decent scores in Value, Dividend, and Resilience, Merck KGaA seems to have a stable financial standing and the ability to weather economic uncertainties. As a global pharmaceutical and chemicals company with a focus on research in areas such as oncology, neurodegenerative diseases, autoimmune, and inflammatory diseases, Merck KGaA‘s diverse product portfolio positions it well for future growth.
Overall, Merck KGaA‘s Smartkarma Smart Scores reflect a company with a balanced mix of growth potential, financial stability, and market performance. With a strong emphasis on research and development in critical health areas, Merck KGaA is well-positioned to navigate challenges and capitalize on opportunities in the pharmaceutical and chemicals industry. Investors may find Merck KGaA an attractive long-term investment option based on its favorable Smart Scores in Growth and Momentum, coupled with its established presence in key markets and diverse product offerings.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
